MedTrace Logo

Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg

NCT00019968 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-10-31

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing melphalan directly to the tumor may kill more tumor cells and cause less damage to healthy tissues. It is not yet known whether melphalan plus tumor necrosis factor is more effective than melphalan alone for soft tissue sarcoma.

PURPOSE: Randomized phase II trial to study the effectiveness of isolated limb perfusion of melphalan with or without tumor necrosis factor in treating patients who have soft tissue sarcoma of the arm or leg.

Conditions

  • Stage IVB Adult Soft Tissue Sarcoma
  • Stage IIB Adult Soft Tissue Sarcoma
  • Stage IIC Adult Soft Tissue Sarcoma
  • Recurrent Adult Soft Tissue Sarcoma
  • Stage IVA Adult Soft Tissue Sarcoma
  • Stage III Adult Soft Tissue Sarcoma

Interventions

DRUG

melphalan

DRUG

tumor necrosis factor

Sponsors & Collaborators

  • National Institutes of Health Clinical Center (CC)

    lead NIH

Principal Investigators

  • H. Richard Alexander, Jr. · National Cancer Institute (NCI)

Study Design

Purpose
TREATMENT

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-08-31
Completion
2002-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00019968 on ClinicalTrials.gov